Elite in Polymyositis

Masataka Kuwana

Tokyo, JP 
Elite in Polymyositis
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Masataka Kuwana practices in Tokyo, Japan. Mr. Kuwana is rated as an Elite expert by MediFind in the treatment of Polymyositis. His top areas of expertise are Myositis, Interstitial Lung Disease, Acute Interstitial Pneumonia, Systemic Sclerosis (SSc), and Splenectomy.

His clinical research consists of co-authoring 371 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 64 articles in the study of Polymyositis.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Japan
Bunkyo, Japan
Sendagi, 1138602, Japan
Shinjuku, 1608582, Japan
Kagoshima, Japan
Chiba, 2618502, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Single Arm, Multi-center Study to Assess the Long-term Real-world Safety and Effectiveness of Nucala in EGPA Patients Who Have Already Used Nucala for at Least 96 Weeks in Japan
A Single Arm, Multi-center Study to Assess the Long-term Real-world Safety and Effectiveness of Nucala in EGPA Patients Who Have Already Used Nucala for at Least 96 Weeks in Japan
Enrollment Status: Completed
Publish Date: September 19, 2024
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
View 2 Less Clinical Trials

371 Total Publications

Clinical Relevance of Tertiary Lymphoid Structures in Connective Tissue Diseases
Clinical Relevance of Tertiary Lymphoid Structures in Connective Tissue Diseases
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: October 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kuwana's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 9 Distinguished Conditions
View All 12 Advanced Conditions
View All 38 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile